Etoposide IC50 for Cell-based and Cell-free Assays

Cell-free Assays (IC₅₀/K_i) for Etoposide

Key Target	IC₅₀ (Cell-free)	Description	Reference
KEAP1 BTB domain	4.51 µM	Virtual screening (molecular docking) with NNScore2	Download PDF
Topo II	2.59 µM	Molecular docking simulation (theoretical IC50 value derived from binding energy).	PMC9392260
KEAP1 BTB domain	4.51 µM	Neural-network-based scoring function (NNScore2) of minimized affinity ligands	Download PDF
Topo II	2.59 μM	Molecular docking simulation	PMC9392260

Cell-based Assay (IC₅₀) for Etoposide

Cell Type	IC₅₀ (Cell-based)	Description	Reference
A549 (lung adenocarcinoma organoid model)	3.238 µM	Cell viability determined by adding CCK8 reagent after 3 days, data analyzed by nonlinear curve fitting in GraphPad Prism 9.	Download PDF
OVCAR3 (human ovarian adenocarcinoma cell line)	12.5 ± 1.8 µM (48h)	MTT assay, nonlinear regression analysis	Download PDF
SKOV3 (human ovarian adenocarcinoma cell line)	18.7 ± 2.1 µM (48h)	MTT assay, nonlinear regression analysis	Download PDF
Sertoli-germ cell co-culture system	200 μM	CCK-8 colorimetric assay for cell viability	Download PDF
K7M2	10 µM	Cell Counting Kit-8 assay, curve fitting	PMC12718598
143B	10 µM	Cell Counting Kit-8 assay, curve fitting	PMC12718598
Toledo	9.81 ± 1.14 nM	The drug concentrations that reduced cell count by 50% (IC50) versus control cells were calculated by nonlinear regression fit of the mean values of data, obtained in triplicate experiments with at least 9 wells for each concentration, using GraphPad Pris	Download PDF
OCI-LY3	7.92 ± 3.6 nM	The drug concentrations that reduced cell count by 50% (IC50) versus control cells were calculated by nonlinear regression fit of the mean values of data, obtained in triplicate experiments with at least 9 wells for each concentration, using GraphPad Pris	Download PDF
SU-DHL10	8.19 ± 0.29 nM	The drug concentrations that reduced cell count by 50% (IC50) versus control cells were calculated by nonlinear regression fit of the mean values of data, obtained in triplicate experiments with at least 9 wells for each concentration, using GraphPad Pris	Download PDF
Capan-1 (pancreatic adenocarcinoma)	0.03 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
HCT-116 (colorectal carcinoma)	3.4 ± 0.1 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
LN-229 (glioblastoma)	3.7 ± 0.1 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
NCI-H460 (lungcarcinoma)	6.1 ± 0.4 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
DND-41 (acute lymphoblastic leukemia)	1.0 ± 0.1 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
HL-60 (acute myeloid leukemia)	0.8 ± 0.1 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
K-562 (chronic myeloid leukemia)	4.0 ± 0.6 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
Z-138 (non-Hodgkin lymphoma)	0.7 ± 0.1 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
NSCLC (human non-small cell lung cancer cell line)	58 μM	Data from GDSC database	Download PDF
SHP77 (SCLC cell line)	18.83 μM	Viability assay	Download PDF
H841 (SCLC cell line)	1.86 μM	Viability assay	Download PDF
H524 (SCLC cell line)	55 nM	Viability assay	Download PDF
H2081 (SCLC cell line)	0.54 nM	Viability assay	Download PDF
H524 (GRN OE SCLC cell line)	> 1uM	Viability assay	Download PDF
H2081 (GRN OE SCLC cell line)	> 1uM	Viability assay	Download PDF
A549	2.53 ± 0.48 µM	MTT assay, concentration-response curve	Download PDF
MCF-7 (human breast cancer cell line)	76.4 µM	MTT viability assay	Download PDF
MDA-MB-231 (human breast cancer cell line)	93.6 µM	MTT viability assay	Download PDF
OT-1 CD8+ T-cells	61 nM	CellTiter-Glo® luminescent cell viability assay, non-linear regression of log10[drug] versus luminescence	Download PDF
Raji (human BL cell line)	1.28 ± 0.22 μM	CCK8 assay (absorbance at 450 nm)	Download PDF
SUDHL6 (human DLBCL cell line)	2.07 ± 0.32 μM	CCK8 assay (absorbance at 450 nm)	Download PDF
HTLA-ER	592 µM	Extrapolated	Download PDF
Capan-1 (pancreatic adenocarcinoma cell line)	0.13 mM	MTT assay	PMC11265520
HCT-116 (colorectal carcinoma cell line)	2.3 mM	MTT assay	PMC11265520
LN229 (glioblastoma cell line)	1.7 mM	MTT assay	PMC11265520
NCI-H1975 (lung carcinoma cell line)	1.1 mM	MTT assay	PMC11265520
DND-41 (acute lymphoblastic leukemia cell line)	0.29 mM	MTT assay	PMC11265520
HL-60 (acute myeloid leukemia cell line)	0.7 mM	MTT assay	PMC11265520
K562 (chronic myeloid leukemia cell line)	1.2 mM	MTT assay	PMC11265520
Z138 (non-Hodgkin's lymphoma cell line)	0.3 mM	MTT assay	PMC11265520
HEK293T CYP2D6*1+POR+B5A	69.9 μM	Dose –Response inhibition (inhibition vs normalized response) analysis in GraphPad	Download PDF
HEK293T CYP2D6*4+POR+B5A	0.42 μM	Dose –Response inhibition (inhibition vs normalized response) analysis in GraphPad	Download PDF
AGS (human gastric adenocarcinoma cell line)	14.81 μM	MTT assay	PMC11231857
SGC-7901 (human gastric adenocarcinoma cell line)	23.81 μM	MTT assay	PMC11231857
CHLA-255, SK-N-AS, SK-N-SH, CHLA-136, SK-N-BE(2) (average of five cell lines)	731.1 ± 68.4 nM (with TME cells); 292.8 ± 67.3 nM (alone)	Cell survival was determined by trypan blue exclusion	Download PDF
CHLA-255, SK-N-SH, SK-N-BE(2) (average of three cell lines)	292.5 ± 42.2 nM (with rTGF-β1 + Galunisertib); 237.7 ± 45.9	Cell viability was evaluated by Trypan Blue exclusion	Download PDF
A549 (human lung cancer)	25.8 ± 0.0008 µM	MTT assay	Download PDF
MDA-MB231 (human triple-negative breast cancer)	27.9 ± 0.002 µM	MTT assay	Download PDF
MCF7 (human hormone-dependent breast cancer)	29.8 ± 0.0007 µM	MTT assay	Download PDF
A549 (human lung cancer cell line)	0.802 ± 0.231 µM	MTT assay	Download PDF
H460 (human lung cancer cell line)	0.842 ± 0.39 µM	MTT assay	Download PDF
HT-29 (human colorectal cancer cell line)	1.25 ± 0.02 µM	MTT assay	Download PDF
Caco-2 (human colorectal cancer cell line)	1.06 ± 0.64 µM	MTT assay	Download PDF
MCF-7 (human breast cancer cell line)	0.751 ± 0.002 µM	MTT assay	Download PDF
MDA-MB-231 (human breast cancer cell line)	0.256 ± 0.046 µM	MTT assay	Download PDF
Jurkat (human T-cell leukemia cell line)	7.09 ± 0.19 µM	MTT assay	Download PDF
Ramos (human B-cell lymphoma cell line)	6.45 ± 0.53 µM	MTT assay	Download PDF
HTLA-230 (human MYCN-amplified NB cell line)	69.79 µM	MTS assay	Download PDF
HTLA-ER (etoposide-resistant human neuroblastoma cell line)	221.4 µM	MTS assay	Download PDF
H128-LM	11.37 µM	CCK8 assay, curve fitting method	Download PDF
A549 (human lung adenocarcinoma epithelial cell)	9.32 ± 0.55 µM	CCK-8 assay	PMC10896134
MCF-7 (human breast cancer cell)	10.94 ± 0.39 µM	CCK-8 assay	PMC10896134
HeLa (human cervical cancer cell)	24.66 ± 0.79 µM	CCK-8 assay	PMC10896134
H446 (human small-lung carcinoma cell)	2.21 ± 0.42 µM	CCK-8 assay	PMC10896134
BEAS-2B (human normal lung epithelial cell)	67.59 ± 2.25 µM	CCK-8 assay	PMC10896134
L02 (human normal hepatic cell)	13.45 ± 1.15 µM	CCK-8 assay	PMC10896134
HaCaT (human normal keratinocyte cell line)	4.86 ± 0.35 μM	MTT assay	PMC10883021
U251 (human glioma cell line)	25.90 µM	MTT assay	Download PDF
EwS spheroids (A673)	9.84 µM	Sigmoidal fit of viability quantification.	Download PDF
EwS spheroids (A673)	2.93 µM	Sigmoidal fit of viability quantification.	Download PDF
EwS spheroids (A673)	0.95 µM	Sigmoidal fit of viability quantification.	Download PDF
EwS spheroids (A673)	0.73 µM	Sigmoidal fit of viability quantification.	Download PDF
HTLA-ER	591.7 ± 45.30 µM	Cell viability assay (as reported by Colla et al. [34])	Download PDF
HSC4	49.60 μM (24h), 7.02 μM (48h), 3.76 μM (72h)	SRB assay, calculated GI50	PMC10676484
SCC9	49.12 μM (24h), 49.02 μM (48h), 14.75 μM (72h)	SRB assay, calculated GI50	PMC10676484
HGF	> 200 μM	SRB assay, calculated GI50	PMC10676484
OCI-LY3 (DLBCL cell line)	7.9 ± 3.6 nM	Nonlinear regression fit of viable cell counts assessed by trypan blue dye exclusion.	Download PDF
Jed66_GB	14 µM	Clonogenic cytotoxic assay	Download PDF
Jed41_GB	29 µM	Clonogenic cytotoxic assay	Download PDF
HL-60 (human AML cell line)	16.06 μM	Sigmoidal dose-response model using Prism software based on MTT assay.	PMC9727342
FTC-133 (follicular thyroid carcinoma)	4.4 μM	Cell viability by WST-8 reagent	Download PDF
A2780 (human ovarian cancer cell line)	1.9 µM	Viability measurement using an enzymatic assay (ApoLive-Glo™ Multiplex Assay)	PMC8649464
Igrov-1 (human ovarian cancer cell line)	1.8 µM	Viability measurement using an enzymatic assay (ApoLive-Glo™ Multiplex Assay)	PMC8649464
BG-1 (human ovarian cancer cell line)	1.7 µM	Viability measurement using an enzymatic assay (ApoLive-Glo™ Multiplex Assay)	PMC8649464
OvCar8 (human ovarian cancer cell line)	1.9 µM	Viability measurement using an enzymatic assay (ApoLive-Glo™ Multiplex Assay)	PMC8649464
SKOV-3 (human ovarian cancer cell line)	1.9 µM	Viability measurement using an enzymatic assay (ApoLive-Glo™ Multiplex Assay)	PMC8649464
SKOV-3luc (human ovarian cancer cell line)	1.9 µM	Viability measurement using an enzymatic assay (ApoLive-Glo™ Multiplex Assay)	PMC8649464
UF-168T (patient-derived primary ovarian cancer cells)	1.8 µM	Viability measurement using an enzymatic assay (ApoLive-Glo™ Multiplex Assay)	PMC8649464
A549 (human alveolar basal epithelial cells)	195 nM	MTT assay	Download PDF
H69AR (SCLC cell line)	>= 7.49 μM	tetrazolium (MTS) assay	Download PDF
MS-1 (SCLC cell line)	>= 7.49 μM	tetrazolium (MTS) assay	Download PDF
SBC-3 (SCLC cell line)	< 7.49 μM	tetrazolium (MTS) assay	Download PDF
SBC-5 (SCLC cell line)	< 7.49 μM	tetrazolium (MTS) assay	Download PDF
H69 (SCLC cell line)	< 7.49 μM	tetrazolium (MTS) assay	Download PDF
H719 (SCLC cell line)	< 7.49 μM	tetrazolium (MTS) assay	Download PDF
H1048 (SCLC cell line)	< 7.49 μM	tetrazolium (MTS) assay	Download PDF
H1105 (SCLC cell line)	< 7.49 μM	tetrazolium (MTS) assay	Download PDF
H1417 (SCLC cell line)	< 7.49 μM	tetrazolium (MTS) assay	Download PDF
DMS53 (SCLC cell line)	< 7.49 μM	tetrazolium (MTS) assay	Download PDF
H1882 (SCLC cell line)	< 7.49 μM	tetrazolium (MTS) assay	Download PDF
Lu-139 (SCLC cell line)	< 7.49 μM	tetrazolium (MTS) assay	Download PDF
MCF-7 (human breast carcinoma cell line)	150 μM (24 hr), 100 μM (48 hr)	MTT assay	Download PDF
MDA-MB-231 (human breast carcinoma cell line)	200 μM (48 hr)	MTT assay	Download PDF
Rb Y79 total cells	143.7 μM (Free ETP), 71.5 μM (Lf-ETP)	MTT assay	PMC8606840
Rb Y79 CSCs	198.1 μM (Free ETP), 129 μM (Lf-ETP)	MTT assay	PMC8606840
Rb Y79 non-CSCs	173.5 μM (Free ETP), 43.27 μM (Lf-ETP)	MTT assay	PMC8606840
NCI-H1417 (small cell lung cancer cell line)	1.75 μM	WST-8 assay	PMC9013643
NCI-H719 (small cell lung cancer cell line)	0.15 μM	WST-8 assay	PMC9013643
NCI-H1882 (small cell lung cancer cell line)	0.45 μM	WST-8 assay	PMC9013643
NCI-H1105 (small cell lung cancer cell line)	0.36 μM	WST-8 assay	PMC9013643
NCI-H1048 (small cell lung cancer cell line)	0.30 μM	WST-8 assay	PMC9013643
NCI-H82 (small cell lung cancer cell line)	0.56 μM	WST-8 assay	PMC9013643
SHP-77 (small cell lung cancer cell line)	44.08 μM	WST-8 assay	PMC9013643
NCI-H841 (small cell lung cancer cell line)	0.81 μM	WST-8 assay	PMC9013643
Lipo-DUE1 (DDLPS)	22.5 µM	MTS assay for cell viability	Download PDF
Lipo246A (DDLPS)	2.72 µM	MTS assay for cell viability	Download PDF
PLS-1 (PLS)	10.66 µM	MTS assay for cell viability	Download PDF
C6 glioma cell cultures	11.5 ± 2.5 μM (MTT Assay), 1.8 ± 0.4 μM (Trypan Blue Assay)	MTT assay, Trypan Blue assay	Download PDF
C6 glioma cells	27.1 ± 4.9 μM	MTT assay	Download PDF
AGS gastric cancer cells	12μM	MTT assay	Download PDF
CT26 (colon cancer cell line)	13.73 ± 5.52 µM (48h), 4.66 ± 0.91 µM (72h)	MTT test	Download PDF
3LL (Lewis lung cancer cell line)	1.17 ± 0.12 µM (48h), 1.01 ± 0.24 µM (72h)	MTT test	Download PDF
SJRHB13758_X1C (diagnostic PDX-derived primary rhabdomyosarcoma cells)	~0.05 µM	Dose response curves and WST-1 assay	PMC8329430
SJRHB13758_X2C (relapse PDX-derived primary rhabdomyosarcoma cells)	~2 µM	Dose response curves and WST-1 assay	PMC8329430
HH cells	6.05 ± 0.74 nM	Cell viability assessed by trypan blue dye exclusion, with IC50 calculated by a nonlinear regression fit of the obtained mean values.	PMC7568761
SNU.AT/RT-9 (AT/RT primary cultured cell)	13.4 ± 4.3 µM	Cell viability was measured using the EZ-cytox kit and IC50 was calculated by nonlinear regression analysis using Prism software.	Download PDF
SNU.AT/RT-10 (AT/RT primary cultured cell)	9.9 ± 0.4 µM	Cell viability was measured using the EZ-cytox kit and IC50 was calculated by nonlinear regression analysis using Prism software.	Download PDF
BT12 (AT/RT cell line)	9.2 ± 0.7 µM	Cell viability was measured using the EZ-cytox kit and IC50 was calculated by nonlinear regression analysis using Prism software.	Download PDF
BT16 (AT/RT cell line)	4.9 ± 2.4 µM	Cell viability was measured using the EZ-cytox kit and IC50 was calculated by nonlinear regression analysis using Prism software.	Download PDF
HB1.F3 (human neural stem cell)	16.3 ± 5.2 µM	Cell viability was measured using the EZ-cytox kit and IC50 was calculated by nonlinear regression analysis using Prism software.	Download PDF
R-NS	2.0 µM	Cell viability measured with MTS assay, IC50 obtained by logistic non-linear regression.	Download PDF
R-shIR	7.7 µM	Cell viability measured with MTS assay, IC50 obtained by logistic non-linear regression.	Download PDF
R-shIR	7.7 µM	Cell viability measured with MTS assay, IC50 obtained by logistic non-linear regression.	Download PDF
R-shIR-A	1.5 µM	Cell viability measured with MTS assay, IC50 obtained by logistic non-linear regression.	Download PDF
R-shIR-B	4.7 µM	Cell viability measured with MTS assay, IC50 obtained by logistic non-linear regression.	Download PDF
R-shIR-A	9.4 µM	Cell viability measured with MTS assay, IC50 obtained by logistic non-linear regression.	Download PDF
R-shIR-B	18.9 µM	Cell viability measured with MTS assay, IC50 obtained by logistic non-linear regression.	Download PDF
R-shIR	2.3 µM	Cell viability measured with MTS assay, IC50 obtained by logistic non-linear regression.	Download PDF
R-shIR-A	1.7 µM	Cell viability measured with MTS assay, IC50 obtained by logistic non-linear regression.	Download PDF
R-shIR-B	2.3 µM	Cell viability measured with MTS assay, IC50 obtained by logistic non-linear regression.	Download PDF
A549 (human lung cancer cell line)	1.17 µM (24h, alone); 0.65 µM (24h, with miRNA-101); 0.84 µM	plotting the relative cell survival versus the etoposide concentration and curve-fit to a sigmoidal dose-response (variable slope) model using GraphPad Prism software	PMC8288490
SPDTO #7 (SCLC patient-derived tumor organoids)	0.5382 µM	Cell viability assay (CellTiter-Glo®)	Download PDF
Saos-2 (osteosarcoma cell line)	11.5 µM	Cellular proliferation assay (MTT assay)	Download PDF
Daoy (medulloblastoma cell line)	6.8 µM	Cellular proliferation assay (MTT assay)	Download PDF
SH-SY5Y (neuroblastoma cell line)	2.8 µM	Cellular proliferation assay (MTT assay)	Download PDF
PC-3 (human prostate cancer cell line)	17.15 µM	MTT assay protocol	Download PDF
NCI-H460 (human lung cancer cell line)	14.28 µM	MTT assay protocol	Download PDF
HeLa (human cervix cancer cell line)	13.34 µM	MTT assay protocol	Download PDF
Y79 (human retinoblastoma cell line)	195.84 nM	Cell Counting Kit-8 (CCK-8) assay	Download PDF
Y79/EDR (human retinoblastoma etoposide drug-resistant subline)	28,609.55 nM	Cell Counting Kit-8 (CCK-8) assay	Download PDF
A549 (human lung cancer cell line)	451.47 μM	MTT assay	Download PDF
HT29 (human colorectal adenocarcinoma cell line)	654.03 μM	MTT assay	Download PDF
EA.hy926 (human umbilical vein, somatic cell hybrid)	155.19 μM	MTT assay	Download PDF
U2OS (human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
SaOS-2 (human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
CAL-72 (human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
MG-63 (human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
HOS (human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
143B/HOS (human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
MNNG/HOS (human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
STA-OS-1 (primary human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
STA-OS-2 (primary human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
STA-OS-3 (primary human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
STA-OS-5 (primary human osteosarcoma cell line)	100 µM	Vybrant® MTT Cell Proliferation Assay	PMC7391428
HM-1	8.2–21.5 × 10^4 nM	Cell viability assay (MTT/WST-1 assay)	Download PDF
HCT-116 (human colorectal cancer cell line)	22.00 ± 1.10 µM	MTT assay	Download PDF
PC-3 (human prostate adenocarcinoma cell line)	2.70 ± 0.05 µM	MTT assay	Download PDF
MCF-7 (human breast cancer cell line)	9.60 ± 0.27 µM	MTT assay	Download PDF
A549 (human lung cancer cell line)	>100 µM	MTT assay	Download PDF
HEF (human embryonic fibroblasts)	>100 µM	MTT assay	Download PDF
K562 (human chronic myelogenous leukemia cell line)	8.47 ± 0.95 µM	MTT assay	Download PDF
NCI-H929 (human multiple myeloma cell line)	0.92 ± 0.03 µM	MTT assay	Download PDF
Jurkat (human acute T-cell leukemia cell line)	0.88 ± 0.74 µM	MTT assay	Download PDF
THP-1 (human acute monocytic leukemia cell line)	0.83 ± 0.21 µM	MTT assay	Download PDF
RPMI8228 (human multiple myeloma cell line)	4.60 ± 0.28 µM	MTT assay	Download PDF
LU-135 (SCLC cell line)	0.242 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
SBC-3 (SCLC cell line)	0.276 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
SBC-5 (SCLC cell line)	0.406 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
LU-134-A (SCLC cell line)	0.407 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H526 (SCLC cell line)	0.515 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H1048 (SCLC cell line)	0.563 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
DMS-273 (SCLC cell line)	0.595 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H211 (SCLC cell line)	0.618 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H187 (SCLC cell line)	0.758 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H748 (SCLC cell line)	0.838 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H209 (SCLC cell line)	0.97 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
IST-SL2 (SCLC cell line)	0.978 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
SW1271 (SCLC cell line)	1.29 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
COR-L279 (SCLC cell line)	1.39 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H1694 (SCLC cell line)	1.52 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
LB647-SCLC (SCLC cell line)	1.77 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
COLO-668 (SCLC cell line)	2.01 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H1876 (SCLC cell line)	2.06 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H1304 (SCLC cell line)	2.34 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H1417 (SCLC cell line)	3.26 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
MS-1 (SCLC cell line)	3.62 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H64 (SCLC cell line)	3.93 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H2081 (SCLC cell line)	4.28 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
LU-139 (SCLC cell line)	4.7 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H69 (SCLC cell line)	5.35 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H1963 (SCLC cell line)	6.37 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H510A (SCLC cell line)	6.78 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H847 (SCLC cell line)	7.38 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H2141 (SCLC cell line)	7.39 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H2196 (SCLC cell line)	8.08 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
IST-SL1 (SCLC cell line)	10.5 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
LU-165 (SCLC cell line)	10.9 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H1688 (SCLC cell line)	11 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H2029 (SCLC cell line)	12.3 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H841 (SCLC cell line)	15.2 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
CPC-N (SCLC cell line)	16.4 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
COR-L95 (SCLC cell line)	17.5 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
DMS-79 (SCLC cell line)	21.4 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
COR-L88 (SCLC cell line)	22 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H2171 (SCLC cell line)	23.8 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
SBC-1 (SCLC cell line)	33.3 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H82 (SCLC cell line)	36 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H1836 (SCLC cell line)	41.1 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H446 (SCLC cell line)	45.6 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H524 (SCLC cell line)	50 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
SHP-77 (SCLC cell line)	57.7 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H1092 (SCLC cell line)	65.2 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H2227 (SCLC cell line)	69.3 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
DMS-53 (SCLC cell line)	71.3 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
HCC-33 (SCLC cell line)	73.8 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H196 (SCLC cell line)	108 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H1436 (SCLC cell line)	133 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
NCI-H345 (SCLC cell line)	162 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
DMS-114 (SCLC cell line)	319 μM	Drug sensitivity data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) database.	PMC6594009
SW1271 (human SCLC cell line)	>10 μmol/L	4-parameter curve fit	Download PDF
SHP77 (human SCLC cell line)	0.057 μmol/L	4-parameter curve fit	Download PDF
NCI-H1436 (human SCLC cell line)	>10 μmol/L	4-parameter curve fit	Download PDF
NCI-H660 (human SCLC cell line)	0.05 μmol/L	4-parameter curve fit	Download PDF
NCI-H1105 (human SCLC cell line)	1.7 μmol/L	4-parameter curve fit	Download PDF
NCI-H1836 (human SCLC cell line)	>2 μmol/L	4-parameter curve fit	Download PDF
NCI-H840 (human SCLC cell line)	0.27 μmol/L	4-parameter curve fit	Download PDF
NCI-H524 (human SCLC cell line)	0.82 μmol/L	4-parameter curve fit	Download PDF
DMS 79 (human SCLC cell line)	<0.01 μmol/L	4-parameter curve fit	Download PDF
COLO668 (human SCLC cell line)	<0.01 μmol/L	4-parameter curve fit	Download PDF
LXFS 650L (human SCLC cell line)	0.01 μmol/L	4-parameter curve fit	Download PDF
NCI-H345 (human SCLC cell line)	0.052 μmol/L	4-parameter curve fit	Download PDF
NCI-H735 (human SCLC cell line)	0.25 μmol/L	4-parameter curve fit	Download PDF
DMS 273 (human SCLC cell line)	0.014 μmol/L	4-parameter curve fit	Download PDF
SCLC lines (human SCLC cell lines)	≫2 μmol/L	4-parameter curve fit	Download PDF
hAFSCs	300 μM (24h), 100 μM (48h), 40 μM (72h)	MTT assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay)	Download PDF
HL-60 (human myeloid leukemia)	0.31±0.24 μM	MTT assay; Reed and Muench’s method	PMC6815755
SMMC-7721 (hepatocellular carcinoma)	8.12±0.72 μM	MTT assay; Reed and Muench’s method	PMC6815755
A-549 (lung cancer)	11.92±0.12 μM	MTT assay; Reed and Muench’s method	PMC6815755
MCF-7 (breast cancer)	32.82±0.44 μM	MTT assay; Reed and Muench’s method	PMC6815755
SW480 (colon cancer)	17.11±0.67 μM	MTT assay; Reed and Muench’s method	PMC6815755
BEAS-2B (normal human pulmonary epithelial cell line)	11.17±0.56 μM	MTT assay; Reed and Muench’s method	PMC6815755
GES-1 (normal human gastric epithelial cell line)	8.89 mM	MTS assay	PMC9071996
MDA-MB-231 (breast cancer cells)	3.97 mM	MTS assay	PMC9071996
RPMI-8226 (multiple myeloma cells)	1.92 mM	MTS assay	PMC9071996
A549 (non-small cell lung cancer cells)	10.89 mM	MTS assay	PMC9071996
A549	451.47 µM	MTT assay	Download PDF
HT-29	155.19 µM	MTT assay	Download PDF
EA.hy926	155.19 µM	MTT assay	Download PDF
AGS (human gastric cancer cell line)	80 ± 2 μM (24h), 45 ± 2 μM (48h)	MTT assay	Download PDF
HL-60 (leukemia)	0.31±0.24 μM	Inhibition of cell viability (MTT assay)	PMC6186772
SMMC-7721 (hepatoma)	8.12±0.72 μM	Inhibition of cell viability (MTT assay)	PMC6186772
A-549 (lung cancer)	11.92±0.12 μM	Inhibition of cell viability (MTT assay)	PMC6186772
MCF-7 (breast cancer)	32.82±0.44 μM	Inhibition of cell viability (MTT assay)	PMC6186772
SW480 (colon cancer)	17.11±0.67 μM	Inhibition of cell viability (MTT assay)	PMC6186772
BEAS-2B (normal human bronchial epithelial cell line)	11.17±0.56 μM	Inhibition of cell viability (MTT assay)	PMC6186772
MEF (primary mouse embryo fibroblast cell line)	1.18 ± 0.40 μM	conventional fluorescence assay (Cyquant direct cell proliferation assays)	Download PDF
MDA-MB-231 (human breast adenocarcinoma cell line)	5.34 ± 0.12 μM	conventional fluorescence assay (Cyquant direct cell proliferation assays)	Download PDF
B16-F10 (murine metastatic melanoma cell line)	2.00 ± 0.44 μM	conventional fluorescence assay (Cyquant direct cell proliferation assays)	Download PDF
SK-N-BE(2) (human neuroblastoma cell line)	11894 nM	Cell Counting Kit-8 (CCK-8) cell viability assay	Download PDF
SK-N-BE(2) (human neuroblastoma cell line)	1512 nM	Cell Counting Kit-8 (CCK-8) cell viability assay	Download PDF
VH-64 (Ewing sarcoma cell line)	0.04 μM	Colony formation assays	Download PDF
TC-71 (Ewing sarcoma cell line)	0.04 μM	Colony formation assays	Download PDF
HROC57	1.1 µg/mL	Cell viability measured using crystal violet assay, drug effects determined at the level of 50% inhibition (IC50) in comparison to control, measured at 570 nm.	PMC6127660
human fetal neurospheres	0.9 μM (for Ki-67); 1.3 μM (for β III-tubulin)	Inhibition of Ki-67 positive nuclei; Increase in β III-tubulin positive area	Download PDF
HCC1937 cells	11.16 ± 1.19 µM	CCK-8 assay	Download PDF
BT-549 cells	7.49 ± 1.08 µM	CCK-8 assay	Download PDF
NCI-H295R cells	1.2µM	Cell viability assay (MTT)	Download PDF
MUC-1 cells	1.2µM	Cell viability assay (MTT)	Download PDF
A2780 (ovarian cancer cell line)	34 μM	Fluorometric Microculture Cytotoxicity Assay (FMCA) and non-linear regression analysis in Prism 5 Software Package	Download PDF
ACHN (renal adenocarcinoma cell line)	1 μM	Fluorometric Microculture Cytotoxicity Assay (FMCA) and non-linear regression analysis in Prism 5 Software Package	Download PDF
H69 (small cell lung cancer cell line)	17 μM	Fluorometric Microculture Cytotoxicity Assay (FMCA) and non-linear regression analysis in Prism 5 Software Package	Download PDF
MCF-7 (breast cancer cell line)	>50 μM	Fluorometric Microculture Cytotoxicity Assay (FMCA) and non-linear regression analysis in Prism 5 Software Package	Download PDF
U-937 (lymphoma cell line)	0.17 μM	Fluorometric Microculture Cytotoxicity Assay (FMCA) and non-linear regression analysis in Prism 5 Software Package	Download PDF
HCT116 (human colon cancer cell line)	6.3 ± 2.8 μM	MTT assay	Download PDF
HCT116-SN38 (human colon cancer cell line)	4.4 ± 3.5 μM	MTT assay	Download PDF
HT29 (human colon cancer cell line)	9.9 ± 3.7 μM	MTT assay	Download PDF
HT29-SN38 (human colon cancer cell line)	38 ± 17 μM	MTT assay	Download PDF
LoVo (human colon cancer cell line)	1.8 ± 1.9 μM	MTT assay	Download PDF
LoVo-SN38 (human colon cancer cell line)	2.7 ± 1.6 μM	MTT assay	Download PDF
DT40 cells	234 nM	clonogenic survival assay	Download PDF
A-673 (Ewing sarcoma cell line)	2.5 µM	Inhibition of cell viability (CellTiter-Blue assay)	Download PDF
RD-ES (Ewing sarcoma cell line)	1.5 µM	Inhibition of cell viability (CellTiter-Blue assay)	Download PDF
SK-ES-1 (Ewing sarcoma cell line)	0.47 µM	Inhibition of cell viability (CellTiter-Blue assay)	Download PDF
MNNGHOS (osteosarcoma cell line)	5.6 µM	Inhibition of cell viability (CellTiter-Blue assay)	Download PDF
U2-OS (osteosarcoma cell line)	6.8 µM	Inhibition of cell viability (CellTiter-Blue assay)	Download PDF
A-204 (rhabdomyosarcoma cell line)	3.5 µM	Inhibition of cell viability (CellTiter-Blue assay)	Download PDF
HT-1080 (fibrosarcoma cell line)	7.4 µM	Inhibition of cell viability (CellTiter-Blue assay)	Download PDF
SK-LMS-1 (leiomyosarcoma cell line)	4.8 µM	Inhibition of cell viability (CellTiter-Blue assay)	Download PDF
SK-UT-1 (leiomyosarcoma cell line)	2.5 µM	Inhibition of cell viability (CellTiter-Blue assay)	Download PDF
SW-872 (liposarcoma cell line)	2.9 µM	Inhibition of cell viability (CellTiter-Blue assay)	Download PDF
PER-403 (NUT midline carcinoma cell line), PER-624 (NUT midline carcinoma cell line), PER-704 (NUT midline carcinoma cell line)	2.4 ±2mM	AlamarBlue assay	PMC3950881
MRC-5 (normal lung fibroblasts)	0.33 µM	MTT reduction assay	Download PDF
AGS (gastric epithelial adenocarcinoma)	0.58 µM	MTT reduction assay	Download PDF
SK-MES-1 (lung cancer cells)	1.83 µM	MTT reduction assay	Download PDF
J82 (bladder carcinoma cells)	3.49 µM	MTT reduction assay	Download PDF
shSAE2-H446	16.65 μM	MTT assay (for cell viability)	Download PDF
shCtrl-H446	27.26 μM	MTT assay (for cell viability)	Download PDF
HeyA8 (ovarian cancer cell line)	42.19 nM	Cell survival determined by crystal violet staining and measurement of absorbance at 570 nm	PMC4522411
Human Neutrophil System (model parameter)	5.2 uM	Emax Model parameter fitting	Download PDF
791T (osteosarcoma cell line)	12.59 mM (normoxia), 35.75 mM (hypoxia)	SRB assay, calculated on GraphPad Prism5 software using the Hill equation	Download PDF
HOS (osteosarcoma cell line)	2.85 mM (normoxia), 5.86 mM (hypoxia)	SRB assay, calculated on GraphPad Prism5 software using the Hill equation	Download PDF
U2OS (osteosarcoma cell line)	0.8 mM (normoxia), 351.5 mM (hypoxia)	SRB assay, calculated on GraphPad Prism5 software using the Hill equation	Download PDF
AGS (human gastric adenocarcinoma cell line)	52 µM	MTT assay, probit analysis	PMC4017472
TC-32.Fb-neo	102 nM	Trypan blue exclusion assay (viable cell count)	Download PDF
TC-32MRP-1.Fb-neo	126 nM	Trypan blue exclusion assay (viable cell count)	Download PDF
HTLA 230	145.60 ± 35.40 µM	CellTiter 96®AQueous One Solution Cell Proliferation Assay	Download PDF
HTLA ER	531.20 ± 147.35 µM	CellTiter 96®AQueous One Solution Cell Proliferation Assay	Download PDF
A549 organoids	3.238 µM	CCK8 reagent to assess cell viability, analyzed by nonlinear curve fitting in GraphPad Prism 9	Download PDF
OVCAR3	25.4 ± 2.1 µM (24h), 12.5 ± 1.8 µM (48h), 8.3 ± 1.2 µM (72h)	MTT assay, nonlinear regression analysis	Download PDF
SKOV3	32.8 ± 3.0 µM (24h), 18.7 ± 2.1 µM (48h), 12.1 ± 1.5 µM (72h	MTT assay, nonlinear regression analysis	Download PDF
Sertoli-germ cell co-culture system	200 μM	CCK-8 assays	Download PDF
PC-3 cells	10.07 µM	Cytotoxicity assay	Download PDF
WPMY-1 cells	12.98 µM	Cytotoxicity assay	Download PDF
PC-3 cells	4.4 µM	in vitro cytotoxic activity assay	Download PDF
WPMY-1 cells	3.8 µM	in vitro cytotoxic activity assay	Download PDF
PC-3 cells	4.4 µM	in vitro cytotoxic activity assay	Download PDF
WPMY-1 cells	3.8 µM	in vitro cytotoxic activity assay	Download PDF
PC-3 cells	10.07 µM	in vitro cytotoxic activity assay	Download PDF
PC-3 cells	4.45 µM	in vitro cytotoxic activity assay	Download PDF
HL-60	10.50 µM	In vitro cytotoxicity assays	Download PDF
PLB-985	15.20 µM	In vitro cytotoxicity assays	Download PDF
Capan-1	0.03 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
HCT-116	3.4 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
LN-229	3.7 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
NCI-H460	6.1 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
DND-41	1.0 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
HL-60	0.8 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
K-562	4.0 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
Z-138	0.7 µM	CellTiter 96®Aqueous Non-Radioactive Cell Proliferation Assay	Download PDF
Toledo	9.81 nM	Trypan blue dye exclusion, counted with a hemocytometer, calculated by nonlinear regression fit	Download PDF
OCI-LY3	7.92 nM	Trypan blue dye exclusion, counted with a hemocytometer, calculated by nonlinear regression fit	Download PDF
SU-DHL10	8.19 nM	Trypan blue dye exclusion, counted with a hemocytometer, calculated by nonlinear regression fit	Download PDF
TR84 (Cancer Cells)	2.98 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR104 (Cancer Cells)	>30 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR105 (Cancer Cells)	4.37 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR93 (Cancer Cells)	20.94 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR100 (Cancer Cells)	5.46 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR102 (Cancer Cells)	>30 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR106 (Cancer Cells)	13.59 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR159 (Cancer Cells)	11.98 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR64 (Cancer Cells)	11.92 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR65 (Cancer Cells)	25.39 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR153 (Cancer Cells)	7.35 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR108 (Cancer Cells)	>30 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR109 (Cancer Cells)	>30 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR84 (Non-Cancer Cells)	1.01 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR104 (Non-Cancer Cells)	15.61 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR105 (Non-Cancer Cells)	2.95 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR93 (Non-Cancer Cells)	7.06 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR100 (Non-Cancer Cells)	1.67 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR102 (Non-Cancer Cells)	12.30 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR106 (Non-Cancer Cells)	7.11 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR159 (Non-Cancer Cells)	1.58 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR64 (Non-Cancer Cells)	18.13 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR65 (Non-Cancer Cells)	2.08 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR153 (Non-Cancer Cells)	1.26 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR108 (Non-Cancer Cells)	>30 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
TR109 (Non-Cancer Cells)	12.28 µM	Immunofluorescence assay followed by non-linear regression analysis using the log (inhibitor) versus normalized response model within GraphPad Prism 8.0.2.	Download PDF
NSCLC	58 μM	determined from the mean IC50 values for NSCLC from the GDSC	Download PDF
SHP77	18.83 µM	Viability assay	Download PDF
H841	1.86 µM	Viability assay	Download PDF
H524	55 nM	Viability assay	Download PDF
H2081	0.54 nM	Viability assay	Download PDF
H524	> 1 µM	Viability assay	Download PDF
H2081	> 1 µM	Viability assay	Download PDF
A549	2.53 ± 0.48 µM	MTT assay	Download PDF
MCF-7	76.4 µM	MTT viability assays	Download PDF
MDA-MB-231	93.6 µM	MTT viability assays	Download PDF
OT-1 CD8+ T-cells	61 nM	CellTiter-Glo® luminescent cell viability assay	Download PDF
Raji	1.28 ± 0.22 μM	CCK8 assay	Download PDF
SUDHL6	2.07 ± 0.32 μM	CCK8 assay	Download PDF
HEK293T CYP2D6*1+POR+B5A	9.3 μM	CellTiter-Glo® luminescent cell viability assay, dose–response inhibition (inhibition vs normalized response) analysis in GraphPad.	Download PDF
HEK293T CYP2D6*4+POR+B5A	4.9 μM	CellTiter-Glo® luminescent cell viability assay, dose–response inhibition (inhibition vs normalized response) analysis in GraphPad.	Download PDF
Capan-1	0.13 mM	MTT assay	PMC11265520
HCT-116	2.3 mM	MTT assay	PMC11265520
LN229	1.7 mM	MTT assay	PMC11265520
NCI-H1975	1.1 mM	MTT assay	PMC11265520
DND-41	0.29 mM	MTT assay	PMC11265520
HL-60	0.7 mM	MTT assay	PMC11265520
K562	1.2 mM	MTT assay	PMC11265520
Z138	0.3 mM	MTT assay	PMC11265520
AGS	14.81 μM	MTT assay	PMC11231857
SGC-7901	23.81 μM	MTT assay	PMC11231857
Neuroblastoma cell lines (average of 5)	292.8 nM	Cell survival was determined by trypan blue exclusion	Download PDF
A549	25.8 ± 0.0008 µM	MTT assay	Download PDF
MDA-MB231	27.9 ± 0.002 µM	MTT assay	Download PDF
MCF7	29.8 ± 0.0007 µM	MTT assay	Download PDF
H128-LM cells	11.37 µM	CCK8 assay, curve fitting method	Download PDF
HaCaT	4.86 ± 0.35 μM	MTT assay	PMC10883021
MCF-7	10.94 ± 0.39 µM	CCK-8 assay	PMC10896134
HeLa	24.66 ± 0.79 µM	CCK-8 assay	PMC10896134
A549	9.32 ± 0.55 µM	CCK-8 assay	PMC10896134
H446	2.21 ± 0.42 µM	CCK-8 assay	PMC10896134
BEAS-2B	67.59 ± 2.25 µM	CCK-8 assay	PMC10896134
L02	13.45 ± 1.15 µM	CCK-8 assay	PMC10896134
TC71	150 nmol/L	CCK-8 reagent assay	PMC10618738
HTLA-230	69.79 µM	MTS assay	Download PDF
HTLA-ER	221.4 µM	MTS assay	Download PDF
EwS spheroids (A673)	9.84 µM	Viability quantification of EwS spheroids using microfluidic protocols, followed by sigmoidal function fitting to determine IC50, with viability assessed by propidium iodide (PI) and GFP signals.	Download PDF
EwS spheroids (A673)	2.93 µM	Viability quantification of EwS spheroids using microfluidic protocols, followed by sigmoidal function fitting to determine IC50, with viability assessed by propidium iodide (PI) and GFP signals.	Download PDF
EwS spheroids (A673)	0.95 µM	Viability quantification of EwS spheroids using microfluidic protocols, followed by sigmoidal function fitting to determine IC50, with viability assessed by propidium iodide (PI) and GFP signals.	Download PDF
EwS spheroids (A673)	0.73 µM	Viability quantification of EwS spheroids using microfluidic protocols, followed by sigmoidal function fitting to determine IC50, with viability assessed by propidium iodide (PI) and GFP signals.	Download PDF
HTLA-ER	591.7 ± 45.30 µM	Reported by Colla et al. [34]	Download PDF
U251	25.90 µM	MTT assay	Download PDF
OCI-LY3	7.9 ± 3.6 nM	Trypan blue dye exclusion, counted with a hemocytometer, nonlinear regression fit.	Download PDF
HSC4	49.60 μM (24h), 7.02 μM (48h), 3.76 μM (72h)	Sulforhodamine B (SRB) assay	PMC10676484
SCC9	49.12 μM (24h), 49.02 μM (48h), 14.75 μM (72h)	Sulforhodamine B (SRB) assay	PMC10676484
HGF	> 200 μM	Sulforhodamine B (SRB) assay	PMC10676484
Jed66_GB	14 µM	Clonogenic cytotoxic assay	Download PDF
Jed41_GB	29 µM	Clonogenic cytotoxic assay	Download PDF
HL-60	16.06 μM	MTT assay, calculated using sigmoidal dose-response model and Prism software	PMC9727342
FTC-133 cells	4.4μM	WST-8 assay	Download PDF
A549 cells	195 nM	MTT assay	Download PDF
A2780	1.2 µM	Enzymatic assay (viability measurement) using ApoLive-Glo™ Multiplex Assay, dose-response curves plotted, IC50 values calculated using GraphPad.	PMC8649464
Igrov-1	1.5 µM	Enzymatic assay (viability measurement) using ApoLive-Glo™ Multiplex Assay, dose-response curves plotted, IC50 values calculated using GraphPad.	PMC8649464
BG-1	1.8 µM	Enzymatic assay (viability measurement) using ApoLive-Glo™ Multiplex Assay, dose-response curves plotted, IC50 values calculated using GraphPad.	PMC8649464
OvCar8	1.6 µM	Enzymatic assay (viability measurement) using ApoLive-Glo™ Multiplex Assay, dose-response curves plotted, IC50 values calculated using GraphPad.	PMC8649464
SKOV-3	1.9 µM	Enzymatic assay (viability measurement) using ApoLive-Glo™ Multiplex Assay, dose-response curves plotted, IC50 values calculated using GraphPad.	PMC8649464
SKOV-3luc	1.7 µM	Enzymatic assay (viability measurement) using ApoLive-Glo™ Multiplex Assay, dose-response curves plotted, IC50 values calculated using GraphPad.	PMC8649464
MCF-7	150 μM (24 hr), 100 μM (48 hr)	MTT assay	Download PDF
MDA-MB-231	200 μM (48 hr)	MTT assay	Download PDF
NCI-H1417	1.75 μM	WST-8 assay; Dose–response curves and IC50 values were calculated using GraphPad Prism 9.	PMC9013643
NCI-H719	0.15 μM	WST-8 assay; Dose–response curves and IC50 values were calculated using GraphPad Prism 9.	PMC9013643
NCI-H1882	0.45 μM	WST-8 assay; Dose–response curves and IC50 values were calculated using GraphPad Prism 9.	PMC9013643
NCI-H1105	0.36 μM	WST-8 assay; Dose–response curves and IC50 values were calculated using GraphPad Prism 9.	PMC9013643
NCI-H1048	0.30 μM	WST-8 assay; Dose–response curves and IC50 values were calculated using GraphPad Prism 9.	PMC9013643
NCI-H82	0.56 μM	WST-8 assay; Dose–response curves and IC50 values were calculated using GraphPad Prism 9.	PMC9013643
SHP-77	44.08 μM	WST-8 assay; Dose–response curves and IC50 values were calculated using GraphPad Prism 9.	PMC9013643
NCI-H841	0.81 μM	WST-8 assay; Dose–response curves and IC50 values were calculated using GraphPad Prism 9.	PMC9013643
Lipo-DUE1	22.5 µM	MTS assays for cell viability	Download PDF
Lipo246A	2.72 µM	MTS assays for cell viability	Download PDF
PLS-1	10.66 µM	MTS assays for cell viability	Download PDF
C6 glioma cells	11.5 µM	MTT assay	Download PDF
C6 glioma cells	0.62 µM	MTT assay	Download PDF
AGS gastric cancer cells	4=μM	MTT assay	Download PDF
HH cells	6.05 ± 0.74 nM	Cell viability assessed by trypan blue dye exclusion and viable cells counted with a hemocytometer; IC50 calculated by a nonlinear regression fit.	PMC7568761
CT26 cells	13.73 ± 5.52 µM	colorimetric MTT test	Download PDF
CT26 cells	4.66 ± 0.91 µM	colorimetric MTT test	Download PDF
3LL cells	1.17 ± 0.12 µM	colorimetric MTT test	Download PDF
3LL cells	1.01 ± 0.24 µM	colorimetric MTT test	Download PDF
SNU.AT/RT-9	13.4 ± 4.3 µM	EZ-cytox kit after 72 h drug treatment, calculated by nonlinear regression analysis using Prism software.	Download PDF
SNU.AT/RT-10	9.9 ± 0.4 µM	EZ-cytox kit after 72 h drug treatment, calculated by nonlinear regression analysis using Prism software.	Download PDF
BT12	9.2 ± 0.7 µM	EZ-cytox kit after 72 h drug treatment, calculated by nonlinear regression analysis using Prism software.	Download PDF
BT16	4.9 ± 2.4 µM	EZ-cytox kit after 72 h drug treatment, calculated by nonlinear regression analysis using Prism software.	Download PDF
HB1.F3	16.3 ± 5.2 µM	EZ-cytox kit after 72 h drug treatment, calculated by nonlinear regression analysis using Prism software.	Download PDF
R-NS	2.0 µM	MTS assay	Download PDF
R-shIR	7.7 µM	MTS assay	Download PDF
R-shIR	45 µM	MTS assay	Download PDF
R-shIR-A	9.4 µM	MTS assay	Download PDF
R-shIR-B	18.9 µM	MTS assay	Download PDF
R-shIR-A	1.5 µM	MTS assay	Download PDF
R-shIR-B	4.7 µM	MTS assay	Download PDF
R-shIR	2.3 µM	MTS assay	Download PDF
R-shIR-A	1.7 µM	MTS assay	Download PDF
R-shIR-B	2.3 µM	MTS assay	Download PDF
SPDTO #7	0.5382 µM	CellTiter-Glo® assay	Download PDF
A549 cells	1.17 µM (24 hours); 0.84 µM (48 hours)	MTT assay; sigmoidal dose-response (variable slope) model	PMC8288490
Saos-2	11.5 µM	MTT proliferation assay	Download PDF
Daoy	6.8 µM	MTT proliferation assay	Download PDF
SH-SY5Y	2.8 µM	MTT proliferation assay	Download PDF
HeLa	13.34 µM	MTT assay	Download PDF
NCI-H460	14.28 µM	MTT assay	Download PDF
PC-3	17.15 µM	MTT assay	Download PDF
A549	451.47 μM	MTT cytotoxicity assay	Download PDF
HT29	654.03 μM	MTT cytotoxicity assay	Download PDF
EA.hy926	155.19 μM	MTT cytotoxicity assay	Download PDF

Check the Etoposide product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Size	Price	Qty
100mg	USD 147
500mg	USD 377
1g	USD 577

Cell-free Assays (IC50/Ki) for Etoposide

Cell-based Assay (IC50) for Etoposide

Jump to

Cell-free Assays (IC₅₀/K_i) for Etoposide

Cell-based Assay (IC₅₀) for Etoposide